雷珠单抗辅助玻璃体切割对增殖性糖尿病视网膜病变患者眼功能的影响
|
摘要
目的探讨雷珠单抗辅助玻璃体切割对增殖性糖尿病视网膜病变(PDR)患者眼功能的影响。方法将慈溪市人民医院2016年1月—2018年6月间收治的200例(271眼) PDR患者随机数字法分为对照组(100例,126眼)和观察组(100例,145眼)。对照组给予玻璃体切割,观察组在玻璃体切割前1周给予注射雷珠单抗。比较2组手术情况、视力、眼压、视网膜厚度、并发症等。通过统计学软件对数据进行分析,进而探讨雷珠单抗辅助玻璃体切割对增殖性糖尿病视网膜病变(PDR)患者眼功能的影响。结果观察组手术时间(71. 8±11. 4) min、电凝止血次数(1. 14±0. 53)次、视网膜裂孔率(5. 51%)均明显低于对照组的手术时间(82. 7±10. 8) min、电凝止血次数(1. 78±0. 52)次、视网膜裂孔率(14. 29%)。治疗后,2组眼压、视力明显改善,观察组优于对照组(均P <0. 05)。观察组术后并发症发生率明显低于对照组(P <0. 05)。患者并发症均经对症治疗后恢复。结论雷珠单抗辅助玻璃体切割可有效降低增殖性糖尿病视网膜病变患者手术时间、电凝止血次数、视网膜裂孔率,有效改善患者眼压及视力,并能减少术后并发症。
Objective To investigate the effect of Lucentis assisted vitrectomy on ocular function in patients with proliferative diabetic retinopathy( PDR). Methods A total of 200 patients( 271 eyes) with PDR in our hospital from January2016 to June 2018 were randomly divided into control group( 100 cases,126 eyes) and observation group( 100 cases,145 eyes). The control group was given vitrectomy,and the observation group was added Lucentis one week prior to vitrectomy. The surgical conditions,visual acuity,intraocular pressure,retinal thickness,and complications were compared between the two groups. The data were analyzed by statistical software to investigate the effect of Lucentis assisted vitrectomy on ocular function in patients with proliferative diabetic retinopathy( PDR). Results The operation time( 71. 8 ±11. 4) min,the electrocoagulation hemostasis number( 1. 14 ± 0. 53) time,and the retinal tear rate( 5. 51%) of the observation group were significantly lower than those of the control group [( 82. 7 ± 10. 8) min,( 1. 78 ± 0. 52) times,14. 29%]. After treatment,the intraocular pressure and visual acuity of the two groups were significantly improved( P <0. 05),and the observation group was superior to the control group( P < 0. 05). The postoperative complications incidence of observation group was significantly lower than that of the control group( P < 0. 05). The patient' s complications were recovered after symptomatic treatment. Conclusion Lucentis assisted vitrectomy can effectively reduce the operation time,electrocoagulation number and retinal tear rate in patients with proliferative diabetic retinopathy,effectively improve intraocular pressure and visual acuity,and reduce postoperative complications.
Objective To investigate the effect of Lucentis assisted vitrectomy on ocular function in patients with proliferative diabetic retinopathy( PDR). Methods A total of 200 patients( 271 eyes) with PDR in our hospital from January2016 to June 2018 were randomly divided into control group( 100 cases,126 eyes) and observation group( 100 cases,145 eyes). The control group was given vitrectomy,and the observation group was added Lucentis one week prior to vitrectomy. The surgical conditions,visual acuity,intraocular pressure,retinal thickness,and complications were compared between the two groups. The data were analyzed by statistical software to investigate the effect of Lucentis assisted vitrectomy on ocular function in patients with proliferative diabetic retinopathy( PDR). Results The operation time( 71. 8 ±11. 4) min,the electrocoagulation hemostasis number( 1. 14 ± 0. 53) time,and the retinal tear rate( 5. 51%) of the observation group were significantly lower than those of the control group [( 82. 7 ± 10. 8) min,( 1. 78 ± 0. 52) times,14. 29%]. After treatment,the intraocular pressure and visual acuity of the two groups were significantly improved( P <0. 05),and the observation group was superior to the control group( P < 0. 05). The postoperative complications incidence of observation group was significantly lower than that of the control group( P < 0. 05). The patient' s complications were recovered after symptomatic treatment. Conclusion Lucentis assisted vitrectomy can effectively reduce the operation time,electrocoagulation number and retinal tear rate in patients with proliferative diabetic retinopathy,effectively improve intraocular pressure and visual acuity,and reduce postoperative complications.
引文
[1]黄玲,徐金华,林琳.雷珠单抗辅助微创玻璃体切割术治疗严重PDR的临床研究[J].国际眼科杂志,2018,18(8):1511-1514.
[2]刘朝辉,高晓虹,栗改云,等.雷珠单抗对增生性糖尿病视网膜病变眼部VEGF-A、VEGF-B、PIGF及玻璃体切除术的影响[J].眼科,2018,27(4):258-263.
[3]李宇博,潘虹. 23G玻璃体切割术联合雷珠单抗治疗增生性糖尿病视网膜病变的临床观察[J].中国医药科学,2018,8(12):21-23,42.
[4]赵芃芃,秦梅.视网膜分支静脉阻塞治疗研究现状[J].眼科新进展,2018,38(5):485-489.
[5]林娜,郑卫东,李波.雷珠单抗联合玻璃体切割术治疗PDR合并早期新生血管性青光眼[J].国际眼科杂志,2018,18(2):294-297.
[6]张梦思,秦萍,徐利辉.玻璃体腔注射雷珠单抗对增殖性糖尿病视网膜病变合并牵拉性视网膜脱离手术效果的影响[J].广东医学,2018,39(2):283-285.
[7]龙婷,陈佳,杜磊,等.雷珠单抗联合玻璃体切割术治疗糖尿病视网膜病变合并新生血管性青光眼[J].眼科新进展,2017,37(12):1182-1184.
[8]李琴,黎智,张少维,等. 23G与20G玻璃体切除术治疗增生型糖尿病视网膜病变的临床观察[J].中国中医眼科杂志,2017,27(4):250-253.
[9]杜立.注射雷珠单抗对手术治疗增殖性糖尿病性视网膜病变的影响[J].北方药学,2017,14(11):26-27.
[10]范思均,蔡春梅,黄厚斌,等.抗VEGF辅助PPV治疗增生性糖尿病视网膜病变的效果及作用机制分析[J].国际眼科杂志,2017,17(10):1908-1911.
[11]张永红,张晓湄,付鹏.玻璃体腔注射雷珠单抗对增殖性糖尿病视网膜病变患者手术后视力的影响[J].河北医学,2017,23(7):1105-1108.
[12]毛子清,游志鹏,周五剑,等.雷珠单抗预防伴有虹膜新生血管的糖尿病视网膜病变术后再出血疗效观察[J].眼科新进展,2017,37(6):539-543.
[13]万晶,孙会,清苏艺.雷珠单抗联合玻璃体切割术对PDR患者视网膜新血管形成的影响[J].检验医学与临床,2017,14(10):1453-1455.
[14]姜生悦.术前玻璃体腔注射雷珠单抗对PDR患者视网膜手术的影响[J].现代医学,2017,45(5):689-692.
[15]冯希敏,祁颖,张凤妍,等.玻璃体内注射雷珠单抗联合玻璃体切割术治疗增生型糖尿病视网膜病变的疗效观察[J].眼科新进展,2016,36(11):1079-1081.
[16]陈博,张宪,杨华静,等.严重PDR玻璃体切割术后雷珠单抗注射的效果观察(英文)[J].国际眼科杂志,2016,16(12):2176-2179.
[17]李琴,王建宏,张明媚,等. 23G玻璃体切割术前玻璃体腔注射雷珠单抗的临床观察[J].国际眼科杂志,2016,16(10):1959-1961.
[18]刘青,艾明.雷珠单抗联合全视网膜光凝辅助玻璃体切割手术治疗糖尿病视网膜病变[J].国际眼科杂志,2016,16(9):1637-1640.
[19]郭翠玲,赵仲平,何琼敏,等.雷珠单抗玻璃体腔注射对增生性糖尿病视网膜病变患者血清血管内皮生长因子的影响[J].医学综述,2016,22(10):1984-1987.
[20]曾乃仁.雷珠单抗对增殖性糖尿病视网膜病变患者行玻璃体切割术的影响及护理[J].中国临床新医学,2016,9(4):344-346.
[21]刘建伟,李聪伶,于海群.雷珠单抗玻璃体内注射对增生型糖尿病视网膜病变玻璃体切割术效果的影响[J].眼科新进展,2016,36(3):265-267.
[22]章晖,叶波,邱新文,等.雷珠单抗辅助23 G玻璃体切割术治疗增生性糖尿病视网膜病变[J].眼科新进展,2014,34(10):975-977.
[23]赵抒羽,梁先军,林英杰,等.增生期糖尿病视网膜病变围手术期注射雷珠单抗的临床观察[J].临床眼科杂志,2014,22(3):237-240.
[24]王云鹏,陈梅珠,陈国苍,等.玻璃体切割联合玻璃体腔注射雷珠单抗治疗DR[J].国际眼科杂志,2014,14(7):1257-1259.
[25]刘艳,吕小辉,刘建伟,等.增生性糖尿病性视网膜病变玻璃体腔注射雷珠单抗后不同时间行玻璃体切割术疗效观察[J].潍坊医学院学报,2014,36(2):106-108.
[2]刘朝辉,高晓虹,栗改云,等.雷珠单抗对增生性糖尿病视网膜病变眼部VEGF-A、VEGF-B、PIGF及玻璃体切除术的影响[J].眼科,2018,27(4):258-263.
[3]李宇博,潘虹. 23G玻璃体切割术联合雷珠单抗治疗增生性糖尿病视网膜病变的临床观察[J].中国医药科学,2018,8(12):21-23,42.
[4]赵芃芃,秦梅.视网膜分支静脉阻塞治疗研究现状[J].眼科新进展,2018,38(5):485-489.
[5]林娜,郑卫东,李波.雷珠单抗联合玻璃体切割术治疗PDR合并早期新生血管性青光眼[J].国际眼科杂志,2018,18(2):294-297.
[6]张梦思,秦萍,徐利辉.玻璃体腔注射雷珠单抗对增殖性糖尿病视网膜病变合并牵拉性视网膜脱离手术效果的影响[J].广东医学,2018,39(2):283-285.
[7]龙婷,陈佳,杜磊,等.雷珠单抗联合玻璃体切割术治疗糖尿病视网膜病变合并新生血管性青光眼[J].眼科新进展,2017,37(12):1182-1184.
[8]李琴,黎智,张少维,等. 23G与20G玻璃体切除术治疗增生型糖尿病视网膜病变的临床观察[J].中国中医眼科杂志,2017,27(4):250-253.
[9]杜立.注射雷珠单抗对手术治疗增殖性糖尿病性视网膜病变的影响[J].北方药学,2017,14(11):26-27.
[10]范思均,蔡春梅,黄厚斌,等.抗VEGF辅助PPV治疗增生性糖尿病视网膜病变的效果及作用机制分析[J].国际眼科杂志,2017,17(10):1908-1911.
[11]张永红,张晓湄,付鹏.玻璃体腔注射雷珠单抗对增殖性糖尿病视网膜病变患者手术后视力的影响[J].河北医学,2017,23(7):1105-1108.
[12]毛子清,游志鹏,周五剑,等.雷珠单抗预防伴有虹膜新生血管的糖尿病视网膜病变术后再出血疗效观察[J].眼科新进展,2017,37(6):539-543.
[13]万晶,孙会,清苏艺.雷珠单抗联合玻璃体切割术对PDR患者视网膜新血管形成的影响[J].检验医学与临床,2017,14(10):1453-1455.
[14]姜生悦.术前玻璃体腔注射雷珠单抗对PDR患者视网膜手术的影响[J].现代医学,2017,45(5):689-692.
[15]冯希敏,祁颖,张凤妍,等.玻璃体内注射雷珠单抗联合玻璃体切割术治疗增生型糖尿病视网膜病变的疗效观察[J].眼科新进展,2016,36(11):1079-1081.
[16]陈博,张宪,杨华静,等.严重PDR玻璃体切割术后雷珠单抗注射的效果观察(英文)[J].国际眼科杂志,2016,16(12):2176-2179.
[17]李琴,王建宏,张明媚,等. 23G玻璃体切割术前玻璃体腔注射雷珠单抗的临床观察[J].国际眼科杂志,2016,16(10):1959-1961.
[18]刘青,艾明.雷珠单抗联合全视网膜光凝辅助玻璃体切割手术治疗糖尿病视网膜病变[J].国际眼科杂志,2016,16(9):1637-1640.
[19]郭翠玲,赵仲平,何琼敏,等.雷珠单抗玻璃体腔注射对增生性糖尿病视网膜病变患者血清血管内皮生长因子的影响[J].医学综述,2016,22(10):1984-1987.
[20]曾乃仁.雷珠单抗对增殖性糖尿病视网膜病变患者行玻璃体切割术的影响及护理[J].中国临床新医学,2016,9(4):344-346.
[21]刘建伟,李聪伶,于海群.雷珠单抗玻璃体内注射对增生型糖尿病视网膜病变玻璃体切割术效果的影响[J].眼科新进展,2016,36(3):265-267.
[22]章晖,叶波,邱新文,等.雷珠单抗辅助23 G玻璃体切割术治疗增生性糖尿病视网膜病变[J].眼科新进展,2014,34(10):975-977.
[23]赵抒羽,梁先军,林英杰,等.增生期糖尿病视网膜病变围手术期注射雷珠单抗的临床观察[J].临床眼科杂志,2014,22(3):237-240.
[24]王云鹏,陈梅珠,陈国苍,等.玻璃体切割联合玻璃体腔注射雷珠单抗治疗DR[J].国际眼科杂志,2014,14(7):1257-1259.
[25]刘艳,吕小辉,刘建伟,等.增生性糖尿病性视网膜病变玻璃体腔注射雷珠单抗后不同时间行玻璃体切割术疗效观察[J].潍坊医学院学报,2014,36(2):106-108.